XM does not provide services to residents of the United States of America.

Belgian insurer Ageas targets average EPS growth of 6-8% until 2027



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Belgian insurer Ageas targets average EPS growth of 6-8% until 2027</title></head><body>

Adds details, CEO and CFO comments, rewrite throughout

By Mathias de Rozario and Dagmarah Mackos

Sept 23 (Reuters) -Ageas said on Monday that it aims to grow its earnings per share by 6% to 8% on average annually under its new strategic plan through 2027, which focuses on expanding products for SMEs, capitalizing on aging population markets, strengthening technical insurance offerings, and increasing margins through new technologies.

The Belgium-based companyaims to reach a holding free cash flow of more than 2.2 billion euros ($2.45 billion) by 2027 and expectsits shareholder remunerations to be more than 1.9 billion euros over the next three years.

Ageas is set to capitalize on growing demand in the pension and savings segment as populations in Europe and Asia age faster.

"We have a tailwind for the coming years in the pension and savings segment, and we are convinced that that will outgrow the traditional life market", CEO Hans De Cuyper said during the company's investor day in London.

Ageas also seeks to extend its offering in the SME market saying it will outperform the rest of the non-life market in the coming years.

It added it has shifted its strategy in the health and protection segment by adopting a localized approach and keeping limited direct involvement to address continued inflation-related pressures following the pandemic.

The company said it was working to sustain and improve its margins with investment in digitalization and AI aiming to drive one third of the margin improvement.

Under the new plan, Ageas will prioritize acquiring cash-generating, controlled entities in existing markets but doesn’t rule out entering new markets, the CFO said. "We will keep looking to add another business, but it's not something we need." Ages confirmed it was on track to reach its 2022 to 2024 targets by the end of the year.


($1 = 0.8965 euros)



Reporting by Mathias de Rozario and Dagmarah Mackoś;

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.